New research examines the adherence rates for system-level performance measures in Canada. Using data from the Canadian Early Arthritis Cohort that spanned eight years, researchers determined the percentage of RA patients seen in yearly follow-up with the number of gaps between visits, the percentage of RA patients treated with a disease-modifying anti-rheumatic drug and number days from diagnosis to the initiation of treatment. The results: High adherence to system-level performance measures was found in this early RA cohort, with small declines in performance with the increasing length overtime…
One Step Closer to Personalized Medicine for RA Patients
New research is translating the molecular signals in RA patients to better understand the earliest signs of disease. The work on using these signs to test the effects of RA treatment may help rheumatologists determine the most effective treatment for individuals…
Study Assesses Immune Checkpoint Inhibitors Safety in Rheumatic Disease
Since they were first introduced in 2011, immune checkpoint inhibitors (ICIs) have become an important treatment for an expanding list of advanced cancers. Some concerns have been raised around the mechanism of action of these immunotherapy agents, making their use in rheumatic diseases (RD) problematical. An article in the March 2018 issue of Arthritis &…
Gut Microbiota Directly Affects Inflammatory Arthritis
Gut microbiota may provide insight into important environmental triggers for autoimmune diseases. New research in mice indicates that intestinal dysbiosis triggers a mucosal immune response that stimulates T and B cells, which are critical to the development of inflammatory arthritis…
RA Patients May Not Receive Needed Osteoporosis Screening & Treatment
New research examined the frequency of osteoporosis screening and treatment for RA patients from 2003–2014, including four years following the release of the 2010 ACR guideline on glucocorticoid-induced osteoporosis prevention and treatment. The results: Approximately half of RA patients for whom treatment was indicated never received osteoporosis medication. Researchers also found that RA patients, despite their increased risk for developing osteoporosis, were not more likely to receive osteoporosis care than OA patients…
Obesity Linked with Disability in RA
(Reuters Health)—Patients with rheumatoid arthritis (RA) may be more likely to become disabled if they’re obese, a U.S. study suggests. Researchers examined data on more than 25,000 patients with RA. Most were overweight or obese when they joined the study. Those who were severely obese were more likely to report some disability at baseline. Over…
New Study Examines the Physical Activity & Joint Symptom Risk
If you’re a middle-aged woman who makes a New Year’s resolution to work out regularly and you keep that promise for only six months, don’t think that will go far in protecting your joints. Researchers in Australia have homed in on the details of the sustained physical activity required to reduce the risk of joint…
Study Finds Pedometers Reduce Fatigue in RA Patients
For people with rheumatoid arthritis (RA), fatigue can be a debilitating symptom that interferes with daily life and significantly reduces quality of life. Managing fatigue can be difficult; it is linked to disease activity and a host of other conditions that commonly accompany RA, such as depression, sleep problems and obesity. A new study, however,…
Cyclophosphamide for Connective Tissue Disease-Associated Interstitial Lung Disease
A recent systematic review found no clear evidence that rheumatoid arthritis patients treated with cyclophosphamide have better lung function than those treated with mycophenolate mofetil. The researchers caution that physicians should expect treatment with cyclophosphamide may only result in a modest improvement in the preservation of forced vital capacity…
Baricitinib Appears Effective in Biologic-Refractory RA
NEW YORK (Reuters Health)—The selective Janus kinase 1 and 2 inhibitor baricitinib appears also to help patients whose rheumatoid arthritis (RA) has not responded adequately to biologic disease-modifying antirheumatic drugs, according to results from the RA-BEACON randomized trial. The previously published overall results from RA-BEACON showed that baricitinib-treated patients had significantly better functional and clinical…
- « Previous Page
- 1
- …
- 25
- 26
- 27
- 28
- 29
- …
- 74
- Next Page »